Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of GM-CSF on T cell responses after hepatitis B vaccination in haemodialysis non-responders
2006-004674-27Phase 3Active
- Sponsor
- Nierstichting
- Start
- Nov 2006
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of molgramostim in hepatitis B (HBV), sponsored by Nierstichting. Primary endpoints: Adequate protective anti-HBs level and HBsAg-specific T cell responses. Started Nov 2006; status: active.
02
Drugs
molgramostim
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on 2006-004674-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004674-27.